The estimated Net Worth of Rohit Kashyap is at least $3.25 Million dollars as of 9 August 2022. Dr Kashyap owns over 12,343 units of MiMedx Inc stock worth over $2,662,146 and over the last 4 years he sold MDXG stock worth over $94,586. In addition, he makes $492,692 as Exec. VP & Chief Commercial Officer at MiMedx Inc.
Dr has made over 2 trades of the MiMedx Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 12,343 units of MDXG stock worth $51,964 on 9 August 2022.
The largest trade he's ever made was selling 12,343 units of MiMedx Inc stock on 9 August 2022 worth over $51,964. On average, Dr trades about 4,223 units every 31 days since 2020. As of 9 August 2022 he still owns at least 430,072 units of MiMedx Inc stock.
You can see the complete history of Dr Kashyap stock trades at the bottom of the page.
Dr. Rohit Kashyap Ph.D. is the Exec. VP & Chief Commercial Officer at MiMedx Inc.
As the Exec. VP & Chief Commercial Officer of MiMedx Inc, the total compensation of Dr D at MiMedx Inc is $492,692. There are 7 executives at MiMedx Inc getting paid more, with Timothy Wright having the highest compensation of $5,069,350.
Dr D is 50, he's been the Exec. VP & Chief Commercial Officer of MiMedx Inc since . There are 18 older and 4 younger executives at MiMedx Inc. The oldest executive at MiMedx Group, Inc is Neil Yeston, 77, who is the Independent Director.
Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin, and Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
MiMedx Inc executives and other stock owners filed with the SEC include: